Stemline Therapeutics, Inc. To Present At BIO CEO & Investor Conference On February 11th

NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 15th annual BIO CEO & Investor Conference on Monday, February 11, 2013 at 2:30 pm ET at the Waldorf Astoria Hotel in New York City.

About Stemline:

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that targets both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated clinical activity, including durable complete responses (CRs), and an overall survival (OS) benefit versus historical controls in Phase 1/2 studies of advanced cancer patients. For more information about Stemline Therapeutics, visit www.stemline.com .
CONTACT: Stemline:                  Mark Jacobson         Director, Corporate Development         Stemline Therapeutics, Inc.         750 Lexington Avenue         Sixth Floor         New York, NY 10022         Tel: 646-502-2307         Email: mjacobson@stemline.com

If you liked this article you might like

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money

Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money

Trial Patient Dies From a Stemline SL-401 Side Effect

Trial Patient Dies From a Stemline SL-401 Side Effect

Trade These 7 Stocks Under $10 for Huge Profits

Trade These 7 Stocks Under $10 for Huge Profits

Insider Trading Alert - STML, ARCC And PATK Traded By Insiders

Insider Trading Alert - STML, ARCC And PATK Traded By Insiders